



ADVANCING DRUGS THROUGH GLYCOSCIENCE®

## **DR. HENRY ESBER NOMINATED TO PRO-PHARMACEUTICALS BOARD OF DIRECTORS**

**Newton, Mass. (April 10, 2006) -- Pro-Pharmaceuticals, Inc. (Amex: PRW)**, a developer of novel carbohydrate-based therapeutic compounds, today announced the nomination of Dr. Henry Esber to its Board of Directors. Dr. Esber will stand for election by the Company's stockholders at the upcoming Annual Meeting to be held on May 25, in Newton, Massachusetts.

"We are pleased that Henry has accepted our invitation to join the Board," said David Platt, Ph.D., Chairman, President & CEO, Pro-Pharmaceuticals, Inc. "His experience and expertise will be invaluable as we advance our carbohydrate-based therapeutic compounds through clinical trials."

"Pro-Pharmaceuticals has made great strides advancing its product development program, in particular with the clinical studies of DAVANAT<sup>®</sup>, its lead carbohydrate compound," said Dr. Esber. "I look forward to working with the Company through its next phase of growth; bringing these compounds to market."

Dr. Esber is the principal at Esber D & D Consulting. From 2001 to 2004 he served as Executive Director and then Senior Consultant Business Development at Charles River Laboratories Discovery and Development Services. He is the co-founder of BioSignature Diagnostics, Inc. and Advanced Drug Delivery, Inc. He also serves on the Scientific Advisory Boards of several biotechnology companies and is the author of more than 130 technical publications. Dr. Esber has more than 25 years of experience in the areas of oncology/tumor immunology and immunotherapy as well as strong knowledge in the field of toxicology and regulatory affairs. Dr. Esber received a B.S. degree in biology from the College of William and Mary, an M.S. degree in public health and parasitology from the University of North Carolina, and a Ph.D. in immunology/microbiology from West Virginia University Medical Center.

### **About DAVANAT<sup>®</sup>**

DAVANAT<sup>®</sup> is a proprietary polysaccharide polymer comprised of mannose and galactose carbohydrates in a CARBOSOME<sup>™</sup> formation that enables the targeted delivery of chemotherapy drugs to protein receptors (lectins) on cancer cells.

### **Pro-Pharmaceuticals, Inc. – Advancing Drugs Through Glycoscience<sup>®</sup>**

Pro-Pharmaceuticals is a development stage company engaged in the discovery, development and commercialization of carbohydrate-based therapeutic compounds for advanced treatment of cancer, as well as liver, microbial, cardiovascular and inflammatory diseases, and viral infections. Initially, the product pipeline is principally focused on increasing the efficacy and decreasing the toxicity of approved chemotherapy drugs. The Company has been conducting clinical and pre-clinical studies with its lead product candidate, DAVANAT<sup>®</sup>, in combination with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin, paclitaxel, cisplatin, and bevacizumab (AVASTIN<sup>®</sup>). Results show that DAVANAT<sup>®</sup> exhibits a broad spectrum of activity with

tested drugs. Founded in 2000, the Company is headquartered in Newton, Mass. Additional information is available at [www.pro-pharmaceuticals.com](http://www.pro-pharmaceuticals.com).

**FORWARD LOOKING STATEMENTS:** Any statements in this news release about future expectations, plans and prospects for the Company, including without limitation statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements as defined in the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those described in such statements. We caution investors that actual results or business conditions may differ materially from those projected or suggested in forward-looking statements as a result of various factors including, but not limited to, the following: uncertainties as to the utility and market for our potential products; uncertainties associated with pre-clinical and clinical trials of our drug delivery candidates; our limited experience in product development and expected dependence on potential licensees and collaborators for commercial manufacturing, sales, distribution and marketing of our potential products; possible development by competitors of competing products and technologies; lack of assurance regarding patent and other protection of our proprietary technology; compliance with and change of government patent regulation of our activities, facilities and personnel; uncertainties as to the extent of reimbursement for our potential products by government and private health insurers; our dependence on key personnel; our history of operating losses and accumulated deficit; and economic conditions related to the biotechnology and biopharmaceutical industry. We cannot assure you that we have identified all the factors that create uncertainties. Readers should not place undue reliance on forward-looking statements.

More information about those risks and uncertainties is contained and discussed in the "Management Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors" sections of the Company's most recent quarterly or annual report and in the Company's other reports filed with the Securities and Exchange Commission. The forward-looking statements represent the Company's views as of the date of this news release and should not be relied upon to represent the Company's views as of a subsequent date. While the Company anticipates that subsequent events may cause the Company's views to change, the Company disclaims any obligation to update such forward-looking statements.

Contact: Pro-Pharmaceuticals, Inc., Anthony D. Squeglia: 617.559.0033; [squeglia@pro-pharmaceuticals.com](mailto:squeglia@pro-pharmaceuticals.com). AVASTIN is a trademark of Genentech, Inc.

DAVANAT and Advancing Drugs Through Glycoscience are registered trademarks of Pro-Pharmaceuticals. CARBOSOME is a trademark of Pro-Pharmaceuticals.